DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+15.82%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$214M
AUM Growth
+$214M
(+3.9%)
Cap. Flow
-$17.1M
Cap. Flow
% of AUM
-8%
Top 10 Holdings %
Top 10 Hldgs %
48%
Holding
93
New
17
Increased
13
Reduced
25
Closed
14
Top Buys
| 1 |
VYNE Therapeutics
VYNE
|
$2.53M |
| 2 |
Indaptus Therapeutics
INDP
|
$2.5M |
| 3 |
Kura Oncology
KURA
|
$2.05M |
| 4 |
CSII
Cardiovascular Systems, Inc.
CSII
|
$1.92M |
| 5 |
Larimar Therapeutics
LRMR
|
$1.67M |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$3.97M |
| 2 |
Insulet
PODD
|
$2.82M |
| 3 |
argenx
ARGX
|
$2.67M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$2.32M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
$2.16M |
Sector Composition
| 1 | Healthcare | 86.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $27.5M | 12.89% | 158,675 -22,862 | -13% | -$3.97M |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $15M | 7.04% | 96,000 +2,000 | +2% | +$313K |
|
3
Stereotaxis
STXS
$261M
| $10.5M | 4.93% | 13,680,554 | – | – |
|
|
AERI
4
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $8.9M | 4.17% | 131,770 -1,000 | -0.8% | -$67.6K |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $8.54M | 4% | 306,119 | – | – |
|
6
AtriCure
ATRC
$1.84B
| $8.53M | 3.99% | 315,345 -73,800 | -19% | -$2M |
|
|
ALDR
7
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $6.26M | 2.93% | 396,013 | – | – |
|
8
Akebia Therapeutics
AKBA
$833M
| $6.1M | 2.85% | 610,738 | – | – |
|
|
BPMC
9
DELISTED
Blueprint Medicines
BPMC
| $5.88M | 2.76% | 92,691 +4,000 | +5% | +$254K |
|
10
DexCom
DXCM
$29.5B
| $5.22M | 2.45% | 55,000 -20,000 | -27% | -$1.9M |
|
|
LMNX
11
DELISTED
Luminex Corp
LMNX
| $5.02M | 2.35% | 169,891 -57,609 | -25% | -$1.7M |
|
12
Ascendis Pharma
ASND
$11.8B
| $4.91M | 2.3% | 73,745 -5,500 | -7% | -$366K |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $4.47M | 2.09% | 45,508 -9,000 | -17% | -$884K |
|
|
14
Kura Oncology
KURA
$686M
| $4.36M | 2.04% | 239,500 +112,500 | +89% | +$2.05M |
|
|
IMMU
15
DELISTED
Immunomedics Inc
IMMU
| $4.33M | 2.03% | 183,000 -97,900 | -35% | -$2.32M |
|
|
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
| $4.32M | 2.02% | 97,764 +3,500 | +4% | +$155K |
|
|
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.15M | 1.94% | 95,242 -31,500 | -25% | -$1.37M |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| $3.95M | 1.85% | 294,511 -29,332 | -9% | -$394K |
|
19
Galapagos
GLPG
$2.07B
| $3.74M | 1.75% | 40,609 +1,000 | +3% | +$92.2K |
|
20
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.47M | 1.62% | 604,652 -370,000 | -38% | -$2.12M |
|
21
iShares Biotechnology ETF
IBB
$5.6B
| $2.87M | 1.34% | 26,100 | – | – |
|
22
Xenon Pharmaceuticals
XENE
$2.98B
| $2.71M | 1.27% | 294,362 -83,333 | -22% | -$767K |
|
|
ACHN
23
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $2.68M | 1.26% | 947,636 +79,364 | +9% | +$225K |
|
|
VBIV
24
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $2.57M | 1.2% | 934,691 -63,309 | -6% | -$174K |
|
|
25
VYNE Therapeutics
VYNE
$8.16M
| $2.53M | 1.19% | +312,000 | New | +$2.53M |
|